Literature DB >> 30205191

Is There an Overlap in Immune Response Between Allergic Bronchopulmonary and Chronic Pulmonary Aspergillosis?

Inderpaul Singh Sehgal1, Hansraj Choudhary2, Sahajal Dhooria1, Ashutosh Nath Aggarwal1, Mandeep Garg3, Arunaloke Chakrabarti2, Ritesh Agarwal4.   

Abstract

BACKGROUND: Chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA) are presumed to represent 2 distinct manifestations of Aspergillus species in the lung.
OBJECTIVE: To investigate any possible overlap of the immunological tests used for diagnosing ABPA in proven cases of CPA.
METHODS: In consecutive subjects with CPA, we calculated the proportion of subjects who tested positive for all the immunological investigations used to diagnose ABPA (Aspergillus fumigatus specific IgE >0.35 kUA/L, total IgE ≥500 IU/mL, and eosinophil count ≥500 cells/μL) or obligatory criteria (A. fumigatus specific IgE >0.35 kUA/L and total IgE ≥500 IU/mL).
RESULTS: A total of 269 subjects (53.5% males) of CPA with the mean (standard deviation [SD]) age of 44.3 (14.7) years were enrolled. The most common underlying disease was previously treated pulmonary tuberculosis (n = 230, 85.5%). Ninety-three (34.6%) subjects had total IgE ≥500 IU/mL, whereas A. fumigatus specific IgE >0.35 kUA/L was seen in 112 (41.6%) subjects. Thirteen (4.8%) subjects met all the immunological criteria for ABPA, whereas 59 (21.9%) subjects met the obligatory criteria. Subjects meeting the obligatory criteria had significantly higher eosinophil count (P ≤ .0001), greater immediate cutaneous reactivity to Aspergillus antigen (CPA-others vs obligatory criteria, 9.8 ± 13.9 vs 13.9 ± 14.9 mm, P value = .048), higher A. fumigatus specific IgG (99.3 ± 61.9 vs 122 ± 66.6 mgA/L, P = .015), and greater number of fungal balls (0.9 ± 0.7 [range, 0-3] vs 1.1 ± 0.9 [range, 0-4], P = .026) compared with those without.
CONCLUSIONS: Approximately 5% of subjects with CPA fulfilled all the immunological criteria used for diagnosing ABPA, whereas 22% met the obligatory criteria for ABPA. Whether these patients would require a different management protocol requires further investigation.
Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABPA; Aspergilloma; Aspergillosis; CCPA; Chronic pulmonary aspergillosis; Tuberculosis

Year:  2018        PMID: 30205191     DOI: 10.1016/j.jaip.2018.08.034

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  3 in total

1.  Serum Cytokines Usefulness for Understanding the Pathology in Allergic Bronchopulmonary Aspergillosis and Chronic Pulmonary Aspergillosis.

Authors:  Yuya Ito; Takahiro Takazono; Yasushi Obase; Susumu Fukahori; Nobuyuki Ashizawa; Tatsuro Hirayama; Masato Tashiro; Kazuko Yamamoto; Yoshifumi Imamura; Naoki Hosogaya; Chizu Fukushima; Yoshitomo Morinaga; Katsunori Yanagihara; Koichi Izumikawa; Hiroshi Mukae
Journal:  J Fungi (Basel)       Date:  2022-04-23

Review 2.  Allergic bronchopulmonary aspergillosis.

Authors:  Ritesh Agarwal; Inderpaul S Sehgal; Sahajal Dhooria; Valliappan Muthu; Kuruswamy T Prasad; Amanjit Bal; Ashutosh N Aggarwal; Arunaloke Chakrabarti
Journal:  Indian J Med Res       Date:  2020-06       Impact factor: 2.375

3.  Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan.

Authors:  Eri Ando; Takamasa Nakasuka; Toshio Kubo; Akihiko Taniguchi; Kiichiro Ninomiya; Yuka Kato; Eiki Ichihara; Kadoaki Ohashi; Kammei Rai; Katsuyuki Hotta; Masaomi Yamane; Nobuaki Miyahara; Masahiro Tabata; Yoshinobu Maeda; Katsuyuki Kiura
Journal:  Intern Med       Date:  2021-08-06       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.